Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PECI CRISPR/Cas9 KO Plasmid (h): sc-406564
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PECI CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PECI genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PECI Antibody (32): sc-136374
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PECI CRISPR/Cas9 KO Plasmid (h) | sc-406564 | 20 µg | $397.00 |
Overview
ECI2 encodes peroxisomal D3,D2-enoyl-CoA isomerase (PECI), an auxiliary enzyme required for peroxisomal β-oxidation of unsaturated fatty acyl-CoAs. PECI catalyzes isomerization steps that enable continued chain shortening and coordination with downstream dehydrogenation and thiolysis reactions, supporting lipid catabolism and cellular energy homeostasis. Through its role in peroxisome-dependent fatty acid metabolism, ECI2 contributes to regulation of lipid signaling, redox balance, and metabolic adaptation under nutrient stress. Dysregulation of peroxisomal β-oxidation and unsaturated fatty acid processing is relevant to metabolic disease mechanisms, lipid storage phenotypes, and broader metabolic remodeling observed in cancer and neurodegeneration research contexts.
PECI CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ECI2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ECI2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ECI2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PECI protein expression.
This CRISPR knockout system enables efficient generation of ECI2-deficient cell models for investigation of PECI signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting ECI2 exon(s) critical for PECI function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple ECI2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PECI CRISPR/Cas9 KO Plasmid (h) and PECI CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ECI2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PECI HDR Plasmid (h) and PECI HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ECI2 homology arms to support homology-directed repair at defined ECI2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.